• Immix Biopharma highlighted NXC-201 BCMA-targeted CAR-T as a lead program for relapsed or refractory AL amyloidosis, a setting with no FDA-approved drugs.
• NEXICART-2 U.S. trial data cited a 95% complete hematologic response rate, versus 0%-10% complete response rates reported for investigator’s-choice regimens.
• Enrollment completed with 45 total patients in March 2026; next update for all 45 patients planned for late Sep 2026 with 1-year follow-up.
• Roadmap calls for a planned BLA submission in 1H 2027; commercial launch plan targets end of 2027.
• Market model estimates about 3,000 U.S. patients per year for NXC-201 in relapsed or refractory AL amyloidosis; cites USD 588K as 2026 BCMA CAR-T pricing reference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on July 03, 2026, and is solely responsible for the information contained therein.